Different influence of Her-2 expression on the prognosis in node-positive and node-negative breast cancer
Wang, Y.; Yao, L.; Liu, Y.-q.; Xu, Y.; Ou, Y.-t.; Li, J.-f.; Wang, T.-f.; Fan, Z.-q.; Fan, T.; Lin, B.-y.; Xie, Y.-t.
Zhonghua Zhong Liu Za Zhi 32(7): 511-514
2010
ISSN/ISBN: 0253-3766 PMID: 21029694 Document Number: 639861
To investigate the prognostic significance of Her-2 expression in node-positive and node-negative breast cancer in Chinese women. The Her-2 expression in breast cancers from 981 patients was detected by immunohistochemistry with anti-Her-2 (CB11) monoclonal antibody. The survival curves were analyzed by Kaplan-Meier method, and Cox regression model was applied to determine whether this factor is an independent predictor of survival in multivariate analysis. Nineteen point seven percent of the patients showed positive Her-2 expression in their tumors. Patients with Her-2-positive tumors tended to be younger. The high level Her-2 expression was significantly associated with negative estrogen receptor and progesterone receptor status in their tumors (P < 0.05). Among 387 patients with node-positive disease, the 5-year disease-free survival (DFS) rate and 5-year overall survival (OS) rate were significantly lower in patients with Her-2-positive tumors than in patients with Her-2-negative tumors (DFS: 48.8% vs. 66.9%, P = 0.009; OS: 55.2% vs. 76.4%, P = 0.001), and Her-2 expression was an independent unfavorable prognostic factor for OS, but not for DFS in patients with node-positive disease. Among 591 patients with node-negative disease, Her-2 expression was not significantly associated with DFS and OS (P > 0.05). Her-2 expression is an important prognostic factor in patients with node-positive disease, but not for patients with node-negative disease in Chinese women.